Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 12:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Primary Disease Clear all
Withdrawn Not applicable Interventional

Shared Decision Making for PTSD in Primary Care

NCT04504149
View directory record Official record
Conditions
PTSD
Interventions
Patient Readiness for Improvement through Motivation, Engagement, and Decision-making for PTSD
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 5, 2022 · Synced Sep 25, 2026, 12:15 PM EDT
Completed Phase 4 Interventional Results available

Pharmacokinetics, Safety, and Tolerability of Subcutaneous GAMUNEX-C in Pediatric Subjects With Primary Immunodeficiency

NCT01465958
View directory record Official record
Conditions
Primary Immunodeficiency
Interventions
GAMUNEX-C
Biological
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
2 Years to 16 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
4
States / cities
Los Angeles, California • Centennial, Colorado • Hollywood, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2015 · Synced Sep 25, 2026, 12:15 PM EDT
Completed Phase 1 Interventional

Treatment of Failing Blebs With Ranibizumab

NCT00570726
View directory record Official record
Conditions
Glaucoma, Open-Angle, Failing Bleb Following Trabeculectomy
Interventions
Ranibizumab (Lucentis)
Drug
Lead sponsor
The New York Eye & Ear Infirmary
Other
Eligibility
40 Years and older
Enrollment
6 participants
Timeline
2000 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 14, 2014 · Synced Sep 25, 2026, 12:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Natural Language Processing and Quality Assessment in Primary Care

NCT01023243
View directory record Official record
Conditions
Diabetes
Interventions
Brochure: Care of the Feet for Those at Risk, Quality Survey: foot exam, tobacco and aspirin use
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
Not listed
Enrollment
389 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 5, 2016 · Synced Sep 25, 2026, 12:15 PM EDT
Completed Not applicable Interventional Results available

A Pilot Study Exploring the Efficacy and Safety of Topical Oxybutynin 3% Gel for Primary Focal Hyperhidrosis in Adolescents and Young Adults

NCT02633371
View directory record Official record
Conditions
Hyperhidrosis
Interventions
Oxybutynin 3% gel
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 25 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 18, 2018 · Synced Sep 25, 2026, 12:15 PM EDT
Terminated Phase 2 Interventional

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer

NCT00004221
View directory record Official record
Conditions
Malignant Ovarian Mixed Epithelial Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Primary Peritoneal Carcinoma, Stage III Ovarian Cancer, Undifferentiated Ovarian Carcinoma
Interventions
Carboplatin, Cyclophosphamide, Filgrastim, Paclitaxel, Peripheral Blood Stem Cell Transplantation, Topotecan Hydrochloride
Drug · Biological · Procedure
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 8, 2017 · Synced Sep 25, 2026, 12:15 PM EDT
Completed Phase 4 Interventional

Trial of Parkinson's And Zoledronic Acid

NCT03924414
View directory record Official record
Conditions
Parkinson Disease, Osteoporosis, Parkinsonism, Parkinson's Disease and Parkinsonism, Atypical Parkinsonism, Progressive Supranuclear Palsy, Multiple System Atrophy, Vascular Parkinsonism, Dementia With Lewy Bodies
Interventions
Zoledronic Acid 5Mg/Bag 100Ml Inj, Placebo
Drug · Other
Lead sponsor
California Pacific Medical Center Research Institute
Other
Eligibility
60 Years and older
Enrollment
2,721 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
77
States / cities
Scottsdale, Arizona • Fayetteville, Arkansas • Little Rock, Arkansas + 58 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Sep 25, 2026, 12:15 PM EDT
Completed Phase 1Phase 2 Interventional

Needle-Knife Fistulotomy Vs. Standard Cannulation Trial

NCT06694038
View directory record Official record
Conditions
Biliary Obstruction Due to Common Bile Duct Stone, Malignant Bile Duct Obstruction
Interventions
Needle Knife Fistulotomy, standard biliary cannulation
Procedure
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced Sep 25, 2026, 12:15 PM EDT
Completed Not applicable Interventional

One-Day Intervention for Depression and Impairment in Migraine Patients

NCT02108678
View directory record Official record
Conditions
Migraine, Depression
Interventions
ACT-ME, Migraine Education Only
Behavioral
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Dec 21, 2017 · Synced Sep 25, 2026, 12:15 PM EDT
Completed Phase 3 Interventional Results available

Study to Monitor Subcutaneous Human Immunoglobulin Administered at Modified Dosing Regimens in Patients With Primary Immunodeficiency Diseases

NCT03939533
View directory record Official record
Conditions
Primary Immune Deficiency Disorder
Interventions
CUTAQUIG
Drug
Lead sponsor
Octapharma
Industry
Eligibility
2 Years to 75 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
18
States / cities
Scottsdale, Arizona • Irvine, California • Santa Barbara, California + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2023 · Synced Sep 25, 2026, 12:15 PM EDT
Active, not recruiting Not applicable Interventional

Mind Body Balance for Pediatric Migraine

NCT04715685
View directory record Official record
Conditions
Headache, Headache Disorders, Headache, Migraine, Migraine, Migraine Disorders, Migraine With Aura, Migraine Without Aura, Chronic Migraine
Interventions
40 minute session, 20 minute session, home practice e-health, home practice handout, phone call
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
10 Years to 17 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Aurora, Colorado • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 25, 2026, 12:15 PM EDT
Not yet recruiting Phase 3 Interventional

Migraine Headaches Elimination With Patent Foramen Ovale-Directed Therapy

NCT07629635
View directory record Official record
Conditions
Migraine Disease, Patent Foramen Ovale
Interventions
Prasugrel 5mg, Transcatheter Closure of Patent Foramen Ovale
Drug · Device
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 25, 2026, 12:15 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

ASCEND: ApproacheS to CHC ImplEmeNtation of SDH Data Collection and Action

NCT03607617
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
SDH Tool
Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
Not listed
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Sep 25, 2026, 12:15 PM EDT
Withdrawn Phase 3 Interventional

XERECEPT® (hCRF) for Primary Glioma Patients Requiring Dexamethasone to Treat Peritumoral Brain Edema

NCT00226668
View directory record Official record
Conditions
Brain Edema, Brain Tumor
Interventions
hCRF, placebo hCRF
Drug
Lead sponsor
Celtic Pharma Development Services
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
24
States / cities
Phoenix, Arizona • La Jolla, California • Newport Beach, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2008 · Synced Sep 25, 2026, 12:15 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Detection and Characterization of Neurologic Manifestations of Inborn and Acquired Errors of Immunity

NCT06169150
View directory record Official record
Conditions
Nervous System Disease, Immune System Disease
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 120 Years
Enrollment
350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2043
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Sep 25, 2026, 12:15 PM EDT
Completed Phase 3 Interventional Results available

Efficacy Study of DX-88 (Ecallantide) to Treat Acute Attacks of Hereditary Angioedema (HAE)

NCT00457015
View directory record Official record
Conditions
Hereditary Angioedema (HAE)
Interventions
ecallantide, Phosphate Buffer Saline (PBS), pH 7.0
Drug
Lead sponsor
Shire
Industry
Eligibility
10 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
42
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Berkeley, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Sep 25, 2026, 12:15 PM EDT
Completed No phase listed Observational

Cognitive Status, Fatigue and Inflammation in Patients With Immune Thrombocytopenia (ITP)

NCT06665308
View directory record Official record
Conditions
Chronic Immune Thrombocytopenia, Primary Immune Thrombocytopenia, Adult Immune Thrombocytopenia
Interventions
No intervention
Other
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
3
States / cities
Los Angeles, California • Boston, Massachusetts • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Sep 25, 2026, 12:15 PM EDT
Completed Phase 2 Interventional

ZD9331 With or Without Topotecan in Treating Patients With Refractory or Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

NCT00014690
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
plevitrexed, topotecan hydrochloride
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Aug 1, 2013 · Synced Sep 25, 2026, 12:15 PM EDT
Completed Phase 1Phase 2 Interventional

Safety of KAI-9803 for Injection With Angioplasty Following Heart Attack

NCT00093197
View directory record Official record
Conditions
Myocardial Infarction
Interventions
KAI-9803 for Injection, Placebo
Drug
Lead sponsor
KAI Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 1, 2011 · Synced Sep 25, 2026, 12:15 PM EDT
Completed Early Phase 1 Interventional

Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies

NCT01760226
View directory record Official record
Conditions
Diffuse Large B Cell Lymphoma, Post Transplant Lymphoproliferative Disorder, Primary Mediastinal (Thymic) Large B-cell Lymphoma
Interventions
DA-EPOCH-R for DLBCL, PTLD, AND PMBCL, Methotrexate, Etoposide, Doxorubicin, Vincristine, Rituximab, Cyclophosphamide, Prednisone, G-CSF
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 30 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 25, 2026, 12:15 PM EDT
Completed Phase 1 Interventional

Study of ANX007 in Participants With Primary Open-angle Glaucoma

NCT04188015
View directory record Official record
Conditions
Open Angle Glaucoma
Interventions
2.5mg ANX007, 5.0mg ANX007, Sham Procedure
Biological · Other
Lead sponsor
Annexon, Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Newport Beach, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2020 · Synced Sep 25, 2026, 12:15 PM EDT
Completed Phase 3 Interventional Results available

A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson's Disease

NCT01176240
View directory record Official record
Conditions
Orthostatic Hypotension, Parkinson's Disease
Interventions
Droxidopa, Placebo
Drug · Other
Lead sponsor
Chelsea Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
60
States / cities
Alabaster, Alabama • Gilbert, Arizona • Phoenix, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Sep 25, 2026, 12:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Preventing Cigarette Use Among Urban Youth Via an M-Health Primary Care Preventive Intervention

NCT03855410
View directory record Official record
Conditions
Tobacco Use, Drug Use, Adolescent Behavior, Alcohol Use, Sexual Risk Behavior
Interventions
S4E, Attention-Matched Control Group
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
13 Years to 21 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
2
States / cities
Ann Arbor, Michigan • Ypsilanti, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced Sep 25, 2026, 12:15 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Sulfation of Bile Acids as a Biomarker for Hepatobiliary Diseases

NCT01200082
View directory record Official record
Conditions
Hepatobiliary Diseases
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 65 Years
Enrollment
430 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2022
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 1, 2023 · Synced Sep 25, 2026, 12:15 PM EDT